2021
High‐Sensitivity Cardiac Troponin T and Recurrent Vascular Events After First Ischemic Stroke
Scheitz J, Lim J, Broersen L, Ganeshan R, Huo S, Sperber P, Piper S, Heuschmann P, Audebert H, Nolte C, Siegerink B, Endres M, Liman T. High‐Sensitivity Cardiac Troponin T and Recurrent Vascular Events After First Ischemic Stroke. Journal Of The American Heart Association 2021, 10: e018326. PMID: 33982599, PMCID: PMC8200699, DOI: 10.1161/jaha.120.018326.Peer-Reviewed Original ResearchConceptsRecurrent vascular eventsModerate ischemic strokeVascular eventsCardiac troponin TIschemic strokePrimary outcomeHs-cTnTCox proportional hazards regression analysisTroponin THigh-sensitivity cardiac troponin TProportional hazards regression analysisSensitivity cardiac troponin TFirst ischemic strokeCardiac troponin levelsHazards regression analysisHs-cTnT levelsIndividualized risk stratificationBackground Recent evidenceUpper reference limitDose-response relationshipCause deathRecurrent strokeTroponin levelsStudy entryVascular risk
2020
Endothelial and Leukocyte-Derived Microvesicles and Cardiovascular Risk After Stroke: PROSCIS-B.
Huo S, Kränkel N, Nave A, Sperber P, Rohmann J, Piper S, Heuschmann P, Landmesser U, Endres M, Siegerink B, Liman T. Endothelial and Leukocyte-Derived Microvesicles and Cardiovascular Risk After Stroke: PROSCIS-B. Neurology 2020, 96: e937-e946. PMID: 33184230, DOI: 10.1212/wnl.0000000000011223.Peer-Reviewed Original ResearchConceptsPlatelet-derived MVsCardiovascular outcomesCause mortalityMyocardial infarctionLong-term cardiovascular outcomesCox proportional hazards modelLeukocyte-derived microvesiclesClass II evidenceWorse cardiovascular outcomesLong-term prognosisKaplan-Meier curvesPlatelet-derived microvesiclesProportional hazards modelRecurrent strokeCardiovascular riskEndothelial dysfunctionIschemic strokeProspective cohortHighest quartileStroke patientsVascular inflammationMild strokeEndothelial microvesiclesLowest quartileHazards model
2019
Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)
Sperber P, Siegerink B, Huo S, Rohmann J, Piper S, Prüss H, Heuschmann P, Endres M, Liman T. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke 2019, 50: 3213-3219. PMID: 31526121, DOI: 10.1161/strokeaha.119.026100.Peer-Reviewed Original ResearchConceptsSecondary vascular eventsFunctional outcomeVascular eventsHigh titersNMDAR1-ABSeronegative patientsSeropositive patientsFirst strokeLong-term clinical outcomesLong-term functional outcomeCombined end pointRecurrent vascular eventsOutcomes of patientsPoor functional outcomeSub-group analysisOutcomes of interestAnti-NMDAAutoimmune encephalitisCardiovascular riskProspective cohortRankin ScaleHazard ratioClinical outcomesNeuroprotective effectsReceptor antibodies